RxDoctor Payments DataLook up a doctor →

Hector Velez Cortes, MD

Hematology & Oncology · Ponce, PRNPI 1952405425

Payments from drug & device makers

$3,136,721in general payments, 2019–2025

Across 337 payments — averaging $9307.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$2.8M
  • Janssen Research & Development, LLC$146K
  • Takeda Pharmaceuticals U.S.A., Inc.$122K
  • Incyte Corporation$43K
  • E.r. Squibb & Sons, L.L.C.$21K
  • Pfizer$13K
  • plus $260 from 7 others
$167in research payments, 2019–2025

Across 1 payment — averaging $167.14 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$167

What the payments were for

  • Consulting fees$28,96886%
  • Speaking & faculty fees$3,56311%
  • Travel & lodging$470%
  • Food & beverage$1,1123%
  • Education$960%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,136,721 in reported general payments places this provider in the 95th percentile of 138 hematology & oncology providers in Puerto Rico.

See all hematology & oncology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$281,054
Medicare patients
40
Services billed
7,761

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide117$2,240,290
IbrancePalbociclib69$1,091,328
TasignaNilotinib Hcl45$746,764
SprycelDasatinib45$568,330
VenclextaVenetoclax33$431,192
PomalystPomalidomide16$365,550
LenvimaLenvatinib Mesylate14$344,705
XtandiEnzalutamide25$344,529
CalquenceAcalabrutinib Maleate21$325,364
Lenalidomide20$292,816
PromactaEltrombopag Olamine26$273,489
LonsurfTrifluridine/Tipiracil Hcl17$268,954
InlytaAxitinib12$245,067
DarzalexDaratumumab43$210,956
VerzenioAbemaciclib12$185,169

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerIbrance, Inlyta, Retacrit, Eliquis$12,685$1,364,264104 claims
E.r. Squibb & Sons, L.L.C.Sprycel, Pomalyst$21,285$933,87961 claims
AstraZenecaCalquence$20$325,36421 claims
Johnson & JohnsonDarzalex, Xarelto$15$220,16859 claims
AmgenProlia$11$46,87326 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 138 hematology & oncology providers in Puerto Rico.

Other hematology & oncology in Ponce

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →